Table 1.
Basic characteristics of the Included Studies.
| Study ID | N(T/C) | Sex(M/F) | Age | TNM stages | Intervention group | Control group | Interested outcomes |
|---|---|---|---|---|---|---|---|
| Ding CJ 2012 (27) | 35/35 | 42/28 | 38-70 | IIIb-IV | 250mL/day,10days/course;4 courses | GP/TP,4 courses | ①②③④⑤⑥ |
| Qi SG 2019 (28) | 70/70 | 72/68 | 45-75 | advanced | 200mL/day;3 courses | GP/AC,3 courses | ①②⑦ |
| Ren JS 2015 (29) | 42/42 | 49/35 | 53-73 | IIIb-IV | 250mL/day,10days/course;2 courses | AP,2 courses | ①②⑤⑧⑨ |
| Wang WM 2011 (30) | 24/28 | 37/15 | 32-75 | IV | 250mL/day,10+ days;2 courses | DP,2 courses | ①②③⑦⑧⑨ |
| Yu F 2007 (31) | 30/30 | 44/16 | 50-78 | IIIb-IV | 250mL/day,10days/course;2-3 courses | DP,2-3 courses | ①②④⑤⑥⑩ |
| Ma CG 2013 (32) | 28/28 | 35/21 | 65-83 | IIIa-IV | 250mL/day,7days/course;3 courses | DP,3 courses | ①②③⑤⑥⑩ |
| Shan HG 2014 (33) | 40/40 | 44/36 | 41-76 | IIIb-IV | 250mL/day,14days/course;2 courses | DP,2 courses | ①②③ |
| Bao Z 2019 (34) | 47/47 | 61/33 | 65-71 | advanced | 250mL/day,21days/course;3 courses | GP,3 courses | ①②⑤⑥⑩ |
| Gui YX 2016 (35) | 45/48 | 64/29 | 36-75 | advanced | 260mL/day,10days/course;4 courses | GP,4 courses | ①②③④⑤⑥⑧⑨ |
| Yao DJ 2013 (36) | 50/50 | 84/16 | 30-70 | III-IV | 250mL/day,28days/course | GP,2 courses | ①②③④⑤⑥ |
| Zhao ZY 2014 (37) | 50/52 | 80/22 | 49-67 | IIIb-IV | 250mL/day,10-14days/course | GP,2-6 courses | ①②③④⑤⑥⑧ |
| Zhang LM 2017 (38) | 52/52 | 59/45 | 41-82 | IIIb-IV | 250mL/day,10days/course;2 courses | GP,2 courses | ①② |
| Huang AX 2014 (39) | 38/38 | 51/25 | 45-75 | IIIb-IV | 250mL/day,7days/course;2 courses | GP,2 courses | ①②③⑤⑥⑩ |
| Song Y 2007 (40) | 59/58 | UN | 60-79 | III-IV | 250mL/day,10days/course;2 courses | GC,2 courses | ①③ |
| He WX 2021 (41) | 48/48 | 58/38 | 56-78 | III-IV | 250mL/day,21days/course;4 courses | GP,4 courses | ①②⑤⑥⑩ |
| Jia J 2020 (42) | 40/40 | 58/22 | 58-78 | III-IV | UN | GP,4 courses | ①②⑤⑥⑩ |
| Li HT 2019 (43) | 40/40 | 53/27 | 47-77 | IIIb-IV | 250mL/day,21days/course;2 courses | GP,2 courses | ①② |
| Liu YF 2021 (44) | 34/34 | 52/16 | 53-77 | III-IV | 250mL/day,10days/course;2 courses | GP,2 courses | ①② |
| Luo BP 2018 (45) | 48/48 | 61/35 | 33-64 | IV | 21days/course;2 courses | GP,2 courses | ①②④⑤⑥ |
| Wang HL 2021 (46) | 53/53 | 58/48 | 47-73 | IIIb-IV | 250mL/day,21days/course;2 courses | GP,2 courses | ①②⑤⑧⑨ |
| Wu ZY 2019 (47) | 28/28 | 29/27 | 38-71 | advanced | 250mL/day,21days/course;2 courses | GP,2 courses | ①②③④⑤⑥ |
| Wang YZ 2007 (48) | 28/27 | 37/12 | 46-75 | IIIb-IV | 250mL/day,21days/course;3 courses | NC,3 courses | ①②③④⑥⑩ |
| Ding PQ 2016 (49) | 60/60 | 78/42 | 62-80 | III-IV | 250mL/day,14days/course;2 courses | NP,2 courses | ①②⑤⑥⑧ |
| Wang TX 2014 (50) | 41/41 | 60/22 | 43-80 | III-IV | 250mL/day,14days/course;2 courses | NP,2 courses | ①②③④⑤⑥⑧ |
| Jia YL 2012 (51) | 72/71 | 98/45 | 60-77 | IIIa-IV | 250mL/day,14days/course;2 courses | NC,2 courses | ①②③⑤⑥⑧⑨ |
| Zhao ZY 2007 (52) | 35/34 | 51/18 | 61-82 | IIIa-IV | 250mL/day,10days/course;2-3 courses | NP,2-3 courses | ①②④⑤⑥⑧ |
| Yu QZ 2007 (53) | 30/32 | 65/19 | 35-76 | III-IV | 250mL/day,8-10days/course;4 courses | NP,4 courses | ①②③⑤⑧ |
| Wang K 2007 (54) | 18/18 | 26/10 | 34-75 | IIIb-IV | 250mL/day,8days/course;3 courses | NP,3 courses | ①②③⑤⑥ |
| Li Y 2007 (55) | 44/43 | 65/22 | 42-81 | advanced | 250mL/day,16days/course;4 courses | NP,4 courses | ①②⑤⑥⑧ |
| Geng L 2004 (56) | 25/15 | 25/15 | 25-68 | III-IV | 250mL/day,21days/course;2 courses | NP,2 courses | ①②③ |
| Lv J 2008 (57) | 40/40 | 65/15 | 51-78 | advanced | 250mL/day,21days/course;2 courses | NP,2 courses | ①②③④⑤⑥⑩ |
| Chen YF 2018 (58) | 40/40 | 45/35 | 42-77 | III-IV | 250mL/day,14days/course;2 courses | NP,2 courses | ①② |
| Zheng JH 2009 (59) | 42/42 | 52/32 | 43-79 | advanced | 250mL/day,8days/course;3 courses | NP,3 courses | ①②④⑤⑥⑧ |
| Zou Y 2005 (60) | 24/24 | 33/15 | 32-72 | IIIa-IV | 250mL/day,21days/course;2 courses | TC,2 courses | ①②③⑧ |
| Luo SZ 2006 (61) | 25/25 | 33/17 | 33-75 | IIIb-IV | 250mL/day,21days/course;2 courses | TP,2 courses | ①②③⑤⑥⑧ |
| Cheng ZJ 2017 (62) | 31/30 | 31/30 | 40-80 | IIIb-IV | 250mL/day,21days/course;2 courses | TP,2 courses | ①②③⑦ |
| Li HT 2012 (63) | 30/30 | 44/16 | 49-82 | IIIb-IV | 250mL/day,10days/course;2 courses | TP,2 courses | ①② |
| Luo SW 2007 (64) | 30/30 | 39/21 | 33-75 | IIIa-IV | 250mL/day,14days/course;2 courses | TP,2 courses | ①③④⑤⑥⑧ |
| Liu R 2011 (65) | 27/27 | 36/18 | 46-78 | IIIa-IV | 250mL/day,15days/course;2 courses | TP,2 courses | ①②④⑤⑥⑧ |
| Li DH 2014 (66) | 50/40 | 57/33 | 38-74 | IIIb-IV | 250mL/day,14days/course;2 courses | TP,2 courses | ①②③④⑤⑥⑩ |
| Wang LY 2009 (67) | 40/40 | 59/21 | 32-67 | IIIa-IV | 250mL/day,10-14days/course;2+ courses | TP,2+ courses | ①②③④⑤⑥⑩ |
| Zhang FL 2008 (68) | 30/30 | 43/17 | 36-73 | IIIa-IV | 250mL/day,10-14days/course;2 courses | TP,2 courses | ①②③④⑤⑥⑧ |
| Zhao Q 2019 (69) | 52/52 | 59/45 | 57-71 | advanced | 250mL/day,21days/course;2 courses | TP,2 courses | ①②③⑤⑧ |
| Wu L 2004 (70) | 30/30 | 46/14 | 32-80 | IIIb-IV | 250mL/day,21days/course;2-3 courses | TP/TC/NP,2-3 courses | ①②⑩ |
N, number of people; T/C, experimental group/control group; M/F, male/female; GP,gemcitabine + cisplatin; TP, paclitaxel/albumin paclitaxel/paclitaxel liposome + cisplatin; AC,pemetrexed + carboplatin; AP, pemetrexed + cisplatin; DP, docetaxel + cisplatin; GC,gemcitabine + carboplatin; NC, vinorelbine + carboplatin; NP, vinorelbine + cisplatin; TC, paclitaxel/albumin paclitaxel/paclitaxel liposome + carboplatin. ①Objective remission rate ORR=(CR+PR)/total cases×100%; ②Disease control rate DCR=(CR+PR+SD)/total cases×100%; ③KPS improvement rate=(number of improved cases + number of stable cases)/total cases; ④incidence of hemoglobin reduction = number of adverse reactions/total number of cases × 100%, calculated in the same way as below; ⑤incidence of leukopenia; ⑥incidence of thrombocytopenia; ⑦simple bone marrow suppression; ⑧incidence of nausea and vomiting; ⑨incidence of diarrhea; ⑩simple gastrointestinal reactions; UN, Unclear.